Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

NCT05756907 is registered in ClinicalTrials.gov with Sonnet BioTherapeutics as lead sponsor.

NCT NCT05756907
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05756907 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Lead sponsor
Sonnet BioTherapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
September 15, 2023
Completion date
January 8, 2026
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, platinum-resistant ovarian cancer